<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
 <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
 <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
 <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and life sciences : Organisms :"/>
 <result pre="Proteins : Immune System Proteins: Antibodies Effective control of early" exact="Zika" post="virus replication by Dengue immunity is associated to the"/>
 <result pre="Proteins: Antibodies Effective control of early Zika virus replication by" exact="Dengue" post="immunity is associated to the length of time between"/>
 <result pre="not mediated by antibodies Time, a critical factor to control" exact="Zika" post="replication by Dengue immunity Serrano-CollazoCrisantaConceptualizationFormal analysisInvestigationMethodologySupervisionValidationWriting – original draftWriting"/>
 <result pre="antibodies Time, a critical factor to control Zika replication by" exact="Dengue" post="immunity Serrano-CollazoCrisantaConceptualizationFormal analysisInvestigationMethodologySupervisionValidationWriting – original draftWriting – review &amp;amp;"/>
 <result pre="between DENV/ZIKV infections has a qualitative impact on controlling early" exact="ZIKV" post="replication. Depletion of DENV2-specific Abs in sera confirmed that"/>
 <result pre="sera confirmed that those type-specific Abs do not contribute to" exact="ZIKV" post="control. We show that the magnitude and durability of"/>
 <result pre="durability of the neutralizing antibodies (nAbs) induced by a secondary" exact="ZIKV" post="infection is modest compared to the response induced after"/>
 <result pre="modest compared to the response induced after a secondary heterologous" exact="DENV" post="infection. Our in vivo results are showing a complex"/>
 <result pre="cells (pDC) correlating with an increase in the frequency of" exact="DENV" post="antigen specific T cells and a significant control of"/>
 <result pre="DENV antigen specific T cells and a significant control of" exact="ZIKV" post="replication which is time dependent. Taken together, our results"/>
 <result pre="time dependent. Taken together, our results suggest that early after" exact="ZIKV" post="infection other mechanisms such as the innate and cellular"/>
 <result pre="cellular immune responses may play a predominant role in controlling" exact="ZIKV" post="replication. Regardless of the time elapsed between infections there"/>
 <result pre="was no evidence of in vivo antibody-dependent enhancement (ADE) of" exact="ZIKV" post="by DENV immunity. These findings have pivotal implications while"/>
 <result pre="evidence of in vivo antibody-dependent enhancement (ADE) of ZIKV by" exact="DENV" post="immunity. These findings have pivotal implications while interpreting ZIKV"/>
 <result pre="by DENV immunity. These findings have pivotal implications while interpreting" exact="ZIKV" post="pathogenesis in flavivirus-experimented populations, diagnostic results interpretation and vaccine"/>
 <result pre="non-human primates and others using humans, we believe that previous" exact="DENV" post="immunity confers some degree of protection against ZIKV infection."/>
 <result pre="that previous DENV immunity confers some degree of protection against" exact="ZIKV" post="infection. However, at least two highly relevant questions remain"/>
 <result pre="remain unanswered. One is precisely if the time between primary" exact="DENV" post="and a subsequent ZIKV infections may play a role"/>
 <result pre="precisely if the time between primary DENV and a subsequent" exact="ZIKV" post="infections may play a role in the degree of"/>
 <result pre="play a role in the degree of protection conferred by" exact="DENV" post="immunity. The second question is related to the mechanisms"/>
 <result pre="we provide evidences that a period of 12 months between" exact="DENV" post="and ZIKV infections has a significant impact controlling ZIKV"/>
 <result pre="evidences that a period of 12 months between DENV and" exact="ZIKV" post="infections has a significant impact controlling ZIKV replication compared"/>
 <result pre="between DENV and ZIKV infections has a significant impact controlling" exact="ZIKV" post="replication compared to a shorter period of 3 months."/>
 <result pre="of 3 months. We also provide evidences that the pre-existing" exact="DENV" post="Abs play no role controlling early ZIKV replication. Our"/>
 <result pre="that the pre-existing DENV Abs play no role controlling early" exact="ZIKV" post="replication. Our results strongly suggest that the mechanisms controlling"/>
 <result pre="ZIKV replication. Our results strongly suggest that the mechanisms controlling" exact="ZIKV" post="replication are related to the complex interaction between the"/>
 <result pre="are within the manuscript and it Supporting Information files. Introduction" exact="Zika" post="virus (ZIKV) spread in the Americas has been linked"/>
 <result pre="unique severe adverse outcomes such as fetal loss [1], congenital" exact="Zika" post="syndrome (CZS) [2], Guillain-Barré syndrome (GBS) [3], and rare"/>
 <result pre="meningoencephalitis [5], myelitis [6], uveitis [7], and severe thrombocytopenia [8]." exact="ZIKV" post="is mainly transmitted through the bite of Aedes aegypti,"/>
 <result pre="vertical transmission [12–14] that increase the spread of the virus." exact="ZIKV" post="and DENV circulate on same geographic areas [15, 16]"/>
 <result pre="[12–14] that increase the spread of the virus. ZIKV and" exact="DENV" post="circulate on same geographic areas [15, 16] posing a"/>
 <result pre="different areas like diagnosis, epidemiology, vaccine design and pathogenesis. While" exact="ZIKV" post="exists as a single serotype, DENV has four related"/>
 <result pre="design and pathogenesis. While ZIKV exists as a single serotype," exact="DENV" post="has four related but antigenically different serotypes. Prior exposure"/>
 <result pre="related but antigenically different serotypes. Prior exposure to a single" exact="DENV" post="serotype predisposes individuals to severe disease upon a secondary"/>
 <result pre="serotype predisposes individuals to severe disease upon a secondary heterologous" exact="DENV" post="infection, and the time interval between infections has been"/>
 <result pre="[17]. A short interval of time between homologous or heterologous" exact="DENV" post="infections usually results in protection from disease, while an"/>
 <result pre="the association of previous flavivirus exposure at any time before" exact="ZIKV" post="infection with the severe adverse outcomes of the infection"/>
 <result pre="infection is still unclear. Previously, we showed that a primary" exact="DENV" post="infection (&amp;gt;2 years) does not result in an increase"/>
 <result pre="infection (&amp;gt;2 years) does not result in an increase in" exact="ZIKV" post="viremia or pathogenesis in a non-human primate model (NHP)"/>
 <result pre="response in DENV-experimented individuals may play a key role limiting" exact="ZIKV" post="infection [26]. Our results on the potential protective role"/>
 <result pre="results on the potential protective role of pre-existing DENV-immunity against" exact="ZIKV" post="infection were validated by subsequent NHP works [27, 28]"/>
 <result pre="little is known about the molecular and immune mechanisms behind" exact="DENV" post="and ZIKV interactions. It has been shown that primary"/>
 <result pre="known about the molecular and immune mechanisms behind DENV and" exact="ZIKV" post="interactions. It has been shown that primary DENV infections"/>
 <result pre="DENV and ZIKV interactions. It has been shown that primary" exact="DENV" post="infections do not induce durable ZIKV cross-neutralizing Abs [31,"/>
 <result pre="been shown that primary DENV infections do not induce durable" exact="ZIKV" post="cross-neutralizing Abs [31, 32] but the contribution of previous"/>
 <result pre="ZIKV cross-neutralizing Abs [31, 32] but the contribution of previous" exact="DENV" post="cross-reacting Abs to controlling early ZIKV replication in vivo"/>
 <result pre="the contribution of previous DENV cross-reacting Abs to controlling early" exact="ZIKV" post="replication in vivo and their impact in ZIKV pathogenesis"/>
 <result pre="controlling early ZIKV replication in vivo and their impact in" exact="ZIKV" post="pathogenesis remains unclear. One of the advantages of NHP"/>
 <result pre="mechanisms behind disease pathogenesis. By using rhesus macaques with primary" exact="DENV" post="infections at two different points of time, followed by"/>
 <result pre="at two different points of time, followed by a secondary" exact="ZIKV" post="infection, we found that the length of time separating"/>
 <result pre="time separating the infections has a qualitative impact on controlling" exact="ZIKV" post="replication. It is known that ZIKV-specific Abs appear in"/>
 <result pre="onset [34] and are responsible for most of the neutralizing" exact="ZIKV" post="activity [32]. However, the extent of the contribution of"/>
 <result pre="However, the extent of the contribution of DENV-Abs early after" exact="ZIKV" post="infection in vivo remains uncertain. For this reason, we"/>
 <result pre="at the contribution of the humoral immune response during early" exact="ZIKV" post="replication. Although cross-binding Abs were detected, previous exposure to"/>
 <result pre="ZIKV replication. Although cross-binding Abs were detected, previous exposure to" exact="DENV" post="has no impact on ZIKV neutralization. That fact was"/>
 <result pre="were detected, previous exposure to DENV has no impact on" exact="ZIKV" post="neutralization. That fact was confirmed by depleting DENV2-specific Abs"/>
 <result pre="by depleting DENV2-specific Abs in sera. Lastly, no evidence of" exact="ZIKV" post="enhancement associated with prior DENV exposure was observed in"/>
 <result pre="sera. Lastly, no evidence of ZIKV enhancement associated with prior" exact="DENV" post="exposure was observed in this study. In addition, we"/>
 <result pre="a period of time of at least 12 months between" exact="DENV" post="and ZIKV infections results in a significant increase in"/>
 <result pre="of time of at least 12 months between DENV and" exact="ZIKV" post="infections results in a significant increase in the frequency"/>
 <result pre="the dendritic plasmacytoid cells (pDCs) in the first days after" exact="ZIKV" post="infection and with a trend to higher frequency of"/>
 <result pre="T cells. Taken together, these data suggest that early after" exact="ZIKV" post="infection the cellular immune response, and not Abs, may"/>
 <result pre="and not Abs, may play a predominant role in controlling" exact="ZIKV" post="replication. This study furthers our understanding of ZIKV pathogenesis"/>
 <result pre="in controlling ZIKV replication. This study furthers our understanding of" exact="ZIKV" post="pathogenesis in flavivirus-experimented populations and is a major contribution"/>
 <result pre="three cohorts were infected with 1 x 106 pfu s.c." exact="ZIKV" post="PRVABC59 on the same day, defining exposure time between"/>
 <result pre="Rico, San Juan, Puerto Rico. Fig 1 Experimental design of" exact="ZIKV" post="infection in DENV-immune and naïve macaques. Two cohorts of"/>
 <result pre="pfu s.c.) at different timepoints. Both cohorts were exposed to" exact="ZIKV" post="strain PRABCV59 (1 x 106 pfu s.c.) on September"/>
 <result pre="September 12th, 2017, along with a third cohort composed of" exact="ZIKV" post="and DENV naïve animals (n = 6). ZIKV infection"/>
 <result pre="2017, along with a third cohort composed of ZIKV and" exact="DENV" post="naïve animals (n = 6). ZIKV infection was performed"/>
 <result pre="composed of ZIKV and DENV naïve animals (n = 6)." exact="ZIKV" post="infection was performed 12 months after DENV infection for"/>
 <result pre="(n = 6). ZIKV infection was performed 12 months after" exact="DENV" post="infection for cohort 1 (n = 6), and 3"/>
 <result pre="for cohort 1 (n = 6), and 3 months after" exact="DENV" post="infection for cohort 2 (n = 4). Serum was"/>
 <result pre="was collected at baseline and days 1 through 7 post" exact="ZIKV" post="infection (p.i.). Sample collection was interrupted by Hurricane María’s"/>
 <result pre="Clinical status and laboratory results To determine how a previous" exact="DENV" post="infection affects the clinical status of non-human primates after"/>
 <result pre="to 0.46) (S2C Fig). This was not observed in the" exact="DENV" post="pre-exposed animals. ZIKV RNAemia is affected by the longevity"/>
 <result pre="Fig). This was not observed in the DENV pre-exposed animals." exact="ZIKV" post="RNAemia is affected by the longevity of previous DENV"/>
 <result pre="animals. ZIKV RNAemia is affected by the longevity of previous" exact="DENV" post="immunity To determine if previous immunity to DENV enhances"/>
 <result pre="of previous DENV immunity To determine if previous immunity to" exact="DENV" post="enhances or reduces ZIKV replication, and how it changes"/>
 <result pre="To determine if previous immunity to DENV enhances or reduces" exact="ZIKV" post="replication, and how it changes depending on the convalescence"/>
 <result pre="replication, and how it changes depending on the convalescence period," exact="ZIKV" post="RNAemia was measured in serum and urine using qRT-PCR."/>
 <result pre="(P = 0.042 vs. naïve and P = 0.019 vs." exact="DENV" post="3M group). By day 5 p.i. all three groups"/>
 <result pre="viremia. However, the set-point viremia in the four animals from" exact="DENV" post="12M group was significantly lower compared to the four"/>
 <result pre="no viral RNA detection in the DENV-middle convalescent group, while" exact="DENV" post="3M animals showed a trend towards an intermittent viremia"/>
 <result pre="days 30 and 60 p.i. all animals tested negative for" exact="ZIKV" post="(Fig 2A and Table 1). Fig 2 Zika RNA"/>
 <result pre="negative for ZIKV (Fig 2A and Table 1). Fig 2" exact="Zika" post="RNA kinetics in serum and RNAemia days per cohort."/>
 <result pre="of time between exposures. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="before are in orange. Naïve animals are in black. (A)" exact="ZIKV" post="genome copies/mL in serum. ZIKV replication was detected in"/>
 <result pre="animals are in black. (A) ZIKV genome copies/mL in serum." exact="ZIKV" post="replication was detected in serum during the first 7"/>
 <result pre="represent the group that it is compared to. 10.1371/journal.pntd.0008285.t001Table 1" exact="ZIKV" post="RNAemia days and neutralizing antibody titers of naïve and"/>
 <result pre="days and neutralizing antibody titers of naïve and DENV-immune macaques." exact="ZIKV" post="RNA detection was consistent in all groups during the"/>
 <result pre="day 3 p.i. Cohort 1 animals had no detection of" exact="ZIKV" post="RNA in serum by day 6 p.i. Mean viremia"/>
 <result pre="per group, during the collection period. The animals exposed to" exact="DENV" post="12 months earlier had the least viremia days in"/>
 <result pre="under the curve (AUC) (P = 0.039) (Fig 2C). Lastly," exact="ZIKV" post="RNA in urine was measured using qRT-PCR, but only"/>
 <result pre="was measured using qRT-PCR, but only one animal from the" exact="DENV" post="3M group (MA023) had detectable levels at day 6"/>
 <result pre="(S3 Fig). These results suggest that a previous infection with" exact="DENV" post="contributes to an earlier and significant control of ZIKV"/>
 <result pre="with DENV contributes to an earlier and significant control of" exact="ZIKV" post="viremia in a subsequent infection, but only if at"/>
 <result pre="two infections To assess the impact of previous exposure to" exact="DENV" post="at different times in a humoral response against a"/>
 <result pre="at different times in a humoral response against a subsequent" exact="ZIKV" post="infection, all sixteen animals were tested for binding Abs"/>
 <result pre="infection, all sixteen animals were tested for binding Abs against" exact="ZIKV" post="and DENV serotypes following ZIKV infection. All three groups"/>
 <result pre="sixteen animals were tested for binding Abs against ZIKV and" exact="DENV" post="serotypes following ZIKV infection. All three groups had levels"/>
 <result pre="tested for binding Abs against ZIKV and DENV serotypes following" exact="ZIKV" post="infection. All three groups had levels of anti-DENV IgM"/>
 <result pre="below the cutoff value during the three collection periods, suggesting" exact="ZIKV" post="infection did not induce DENV-specific IgM response (S4A Fig)."/>
 <result pre="not induce DENV-specific IgM response (S4A Fig). As expected, all" exact="DENV" post="immune animals had detectable IgG levels against DENV at"/>
 <result pre="expected, all DENV immune animals had detectable IgG levels against" exact="DENV" post="at baseline (S4B Fig). Anti-DENV IgG levels were confirmed"/>
 <result pre="0.005; mean diff: -0.3, CI95% -0.4997 to -0.1003 for the" exact="DENV" post="3M and DENV 12M groups respectively). Those cross-reacting Abs"/>
 <result pre="-0.3, CI95% -0.4997 to -0.1003 for the DENV 3M and" exact="DENV" post="12M groups respectively). Those cross-reacting Abs were also significantly"/>
 <result pre="30 (P&amp;lt;0.0001; mean diff.: 0.96, CI95%: 0.61 to 1.30 for" exact="DENV" post="12M vs naïve at 30 days p.i,; P&amp;lt;0.0001; mean"/>
 <result pre="p.i,; P&amp;lt;0.0001; mean diff.: 0.75, CI95%: 0.37 to 1.14 for" exact="DENV" post="3M vs naïve at 30 days p.i.; P&amp;lt;0.0001; mean"/>
 <result pre="p.i.; P&amp;lt;0.0001; mean diff.: 0.88, CI95%: 0.54 to 1.23 for" exact="DENV" post="12M vs naïve at 60 days p.i.; P&amp;lt;0.001; mean"/>
 <result pre="p.i.; P&amp;lt;0.001; mean diff.: 0.68, CI95%: 0.29 to 1.07 for" exact="DENV" post="3M vs naïve at 60 days p.i.), slowly decreasing"/>
 <result pre="Abs were early detected only in three animals from the" exact="DENV" post="12M group with two subjects showing a peak on"/>
 <result pre="suggesting a strong cross-reactivity between previously generated anti-DENV IgG to" exact="ZIKV" post="(S4D Fig). DENV-early convalescent animals had significantly higher levels"/>
 <result pre="and P&amp;lt;0.0001; mean diff.: -1.176, CI95%: -1.716 to -0.636 for" exact="DENV" post="3M and DENV 12M groups respectively (S4D Fig). The"/>
 <result pre="diff.: -1.176, CI95%: -1.716 to -0.636 for DENV 3M and" exact="DENV" post="12M groups respectively (S4D Fig). The same scenario can"/>
 <result pre="animals (P&amp;lt;0.01; mean diff.: 1.05, CI95%: 0.2608 to 1.836 for" exact="DENV" post="12M vs. DENV 3M; P&amp;lt;0.0001; mean diff.: 2.15, CI95%:"/>
 <result pre="diff.: 1.05, CI95%: 0.2608 to 1.836 for DENV 12M vs." exact="DENV" post="3M; P&amp;lt;0.0001; mean diff.: 2.15, CI95%: 1.45 to 2.859"/>
 <result pre="3M; P&amp;lt;0.0001; mean diff.: 2.15, CI95%: 1.45 to 2.859 for" exact="DENV" post="12M vs naïve). These levels decreased by day 60"/>
 <result pre="more dramatic in the pre-immune animals (S4E Fig). Abs against" exact="ZIKV" post="EDIII were also measured in order to determine their"/>
 <result pre="to humoral immunity and for their known specific contribution to" exact="ZIKV" post="neutralization (S4F Fig). Only one animal from the DENV-middle"/>
 <result pre="DENV-middle convalescent group showed detectable levels of anti-ZIKV EDIII before" exact="ZIKV" post="infection. Anti-ZIKV EDIII levels for all groups slowly increased"/>
 <result pre="levels (P&amp;lt;0.05; mean diff.: -0.85, CI95%: -1.68 to -0.03 for" exact="DENV" post="12M animals, and P&amp;lt;0.001; mean diff.: -1.26, CI95%: -2.27"/>
 <result pre="and P&amp;lt;0.001; mean diff.: -1.26, CI95%: -2.27 to -0.25 for" exact="DENV" post="3M animals). No significant differences were observed among the"/>
 <result pre="were observed among the groups, suggesting that previous exposure to" exact="DENV" post="does not have an impact on the generation of"/>
 <result pre="have an impact on the generation of cross-reactive Abs against" exact="ZIKV" post="EDIII epitopes and that these Abs may have limited"/>
 <result pre="epitopes and that these Abs may have limited contribution to" exact="ZIKV" post="neutralization. The time between DENV/ZIKV infections modifies the neutralizing"/>
 <result pre="Abs to the neutralization and the impact of a previous" exact="DENV" post="infection in a subsequent ZIKV infection in terms of"/>
 <result pre="the impact of a previous DENV infection in a subsequent" exact="ZIKV" post="infection in terms of neutralization potential, all three groups"/>
 <result pre="three groups were tested using PRNT and FRNT assays against" exact="ZIKV" post="and the four DENV serotypes respectively. Neutralization assays were"/>
 <result pre="using PRNT and FRNT assays against ZIKV and the four" exact="DENV" post="serotypes respectively. Neutralization assays were completed for baseline, days"/>
 <result pre="assays were completed for baseline, days 30 and 60 for" exact="DENV" post="and ZIKV. To better understand if the previous DENV"/>
 <result pre="for DENV and ZIKV. To better understand if the previous" exact="DENV" post="immunity plays a role in the neutralization of ZIKV"/>
 <result pre="previous DENV immunity plays a role in the neutralization of" exact="ZIKV" post="early after the infection, we also ran PRNT assays"/>
 <result pre="expected, all three groups had low or absent nAbs against" exact="ZIKV" post="at baseline (Fig 3A). As early as 6 days"/>
 <result pre="after the infection an increase in the neutralizing activity against" exact="ZIKV" post="is detected in all groups with a slight non-significant"/>
 <result pre="with a slight non-significant trend to be higher in the" exact="DENV" post="12M group. This increase continues on day 7 with"/>
 <result pre="higher levels of dilution effective for half-maximum neutralization compared to" exact="DENV" post="3M and naïve groups. These levels decline slightly by"/>
 <result pre="(Fig 3A). Fig 3 Geometric mean titers of dengue and" exact="ZIKV" post="neutralizing antibodies. The 50% effective concentration of neutralizing antibodies"/>
 <result pre="and confidence intervals. (A) EC50 values of neutralizing antibodies against" exact="ZIKV" post="after ZIKV infection. (B) EC50 values of neutralizing antibodies"/>
 <result pre="intervals. (A) EC50 values of neutralizing antibodies against ZIKV after" exact="ZIKV" post="infection. (B) EC50 values of neutralizing antibodies against DENV2"/>
 <result pre="infection. (B) EC50 values of neutralizing antibodies against DENV2 after" exact="ZIKV" post="infection. Statistically significant differences among groups were calculated by"/>
 <result pre="highest serum concentrations in the magnitude of the neutralization against" exact="ZIKV" post="(only dilutions showing more than 60% of neutralization were"/>
 <result pre="neutralization were considered) on day 6 (P&amp;lt;0.001 and P&amp;lt;0.029 for" exact="DENV" post="12M and DENV 3M vs. naïve respectively at 1:20"/>
 <result pre="on day 6 (P&amp;lt;0.001 and P&amp;lt;0.029 for DENV 12M and" exact="DENV" post="3M vs. naïve respectively at 1:20 dilution and P"/>
 <result pre="at 1:20 dilution and P = 0.0005 and P&amp;lt;0.0001 for" exact="DENV" post="12M vs. DENV 3M and naïve respectively at 1:40"/>
 <result pre="and P = 0.0005 and P&amp;lt;0.0001 for DENV 12M vs." exact="DENV" post="3M and naïve respectively at 1:40 dilution) and day"/>
 <result pre="at 1:40 dilution) and day 7 (P&amp;lt;0.0039 and P&amp;lt;0.0001 for" exact="DENV" post="12M vs. naïve at 1:20 and 1:40 dilutions respectively)"/>
 <result pre="are analyzed together (Table 1). On the other hand, both" exact="DENV" post="immune groups had high levels of nAbs against DENV2"/>
 <result pre="of nAbs against DENV2 at baseline, which boosted significantly for" exact="DENV" post="12M animals at day 30 p.i. compared to the"/>
 <result pre="p.i., these nAbs did not decline in neither of the" exact="DENV" post="immune groups, and a significant difference was still present"/>
 <result pre="was still present for DENV-middle convalescent animals, which suggests that" exact="ZIKV" post="infection induced a boost in cross-neutralizing Abs to DENV"/>
 <result pre="that ZIKV infection induced a boost in cross-neutralizing Abs to" exact="DENV" post="and the magnitude of the boost depend on the"/>
 <result pre="magnitude of the boost depend on the time elapse between" exact="DENV" post="and ZIKV infection (P = 0.0006 for day 30"/>
 <result pre="the boost depend on the time elapse between DENV and" exact="ZIKV" post="infection (P = 0.0006 for day 30 p.i. and"/>
 <result pre="by day 60 p.i. (Fig 3B). Next, to assess pre-existing" exact="DENV" post="Ab responses and their contribution to early ZIKV control,"/>
 <result pre="assess pre-existing DENV Ab responses and their contribution to early" exact="ZIKV" post="control, depletion of DENV-2 specific Abs in serum from"/>
 <result pre="to limited amount of serum, only 4 animals from the" exact="DENV" post="12M group and 2 animals from the naïve group"/>
 <result pre="removal of type-specific Abs (Fig 4C). On the other hand," exact="ZIKV" post="neutralization remained unchanged after depletion of DENV-2 Abs, indicating"/>
 <result pre="Abs make up most of the neutralizing force early during" exact="ZIKV" post="infection regardless of any pre-existing DENV immunity (Fig 4D)."/>
 <result pre="neutralizing force early during ZIKV infection regardless of any pre-existing" exact="DENV" post="immunity (Fig 4D). Fig 4 Pre-existing DENV-2 antibodies have"/>
 <result pre="Fig 4 Pre-existing DENV-2 antibodies have no effect on early" exact="ZIKV" post="neutralization. Depletion of DENV-2 specific antibodies and its effect"/>
 <result pre="specific antibodies and its effect on neutralization against DENV-2 and" exact="ZIKV" post="is shown. Animals from cohort 1 are shown in"/>
 <result pre="density (OD) reduction difference between control and depleted samples. (C)" exact="DENV" post="neutralization titers of depleted and control sera from day"/>
 <result pre="titers of depleted and control sera from day 7 after" exact="ZIKV" post="infection are shown. (D) ZIKV neutralization titers of depleted"/>
 <result pre="sera from day 7 after ZIKV infection are shown. (D)" exact="ZIKV" post="neutralization titers of depleted and control sera from day"/>
 <result pre="performed at 30 days p.i. against two recently circulating contemporary" exact="ZIKV" post="strains, ZIKVH/PF/2013 and ZIKVPRVABC-59. No differences in the neutralization"/>
 <result pre="(S6A Fig). When evaluating the neutralizing titers against all four" exact="DENV" post="serotypes, we observed a boost in neutralization against all"/>
 <result pre="all serotypes in all three groups, suggesting that a subsequent" exact="ZIKV" post="infection impact the levels of heterologous DENV-neutralizing Abs (S6B"/>
 <result pre="of heterologous DENV-neutralizing Abs (S6B Fig). Interestingly 30 days after" exact="ZIKV" post="infection there was a non-significant trend to higher neutralizing"/>
 <result pre="titers against DENV2 and DENV4 compared to the other two" exact="DENV" post="serotypes in the DENV naive group. The hierarchy of"/>
 <result pre="DENV4 compared to the other two DENV serotypes in the" exact="DENV" post="naive group. The hierarchy of neutralizing Abs generated 30"/>
 <result pre="Abs generated 30 days p.i. was the same for both" exact="DENV" post="immune groups (D2&amp;gt;ZIKV&amp;gt;D4&amp;gt;D3&amp;gt;D1), and for the naïve group it"/>
 <result pre="are no differences in the magnitude of cross-neutralization of heterologous" exact="DENV" post="serotypes between DENV-immune groups in spite of the different"/>
 <result pre="time length between DENV/ZIKV infections To assess if a previous" exact="DENV" post="infection has an impact on the T cell response"/>
 <result pre="has an impact on the T cell response to a" exact="ZIKV" post="infection, their effector responses were measured. CD4+ and CD8+"/>
 <result pre="The IFNγ response in the CD4+ T cells from the" exact="DENV" post="12M group before ZIKV infection is remarkable (Fig 5A,"/>
 <result pre="the CD4+ T cells from the DENV 12M group before" exact="ZIKV" post="infection is remarkable (Fig 5A, upper panel, left). The"/>
 <result pre="group was significantly higher in response to the whole inactivated" exact="DENV" post="in comparison with the naïve animals (P&amp;lt;0.05) and although"/>
 <result pre="a higher frequency in response to peptides derived from the" exact="DENV" post="and ZIKV envelopes and ZIKV non-structural proteins as well"/>
 <result pre="frequency in response to peptides derived from the DENV and" exact="ZIKV" post="envelopes and ZIKV non-structural proteins as well compared to"/>
 <result pre="to peptides derived from the DENV and ZIKV envelopes and" exact="ZIKV" post="non-structural proteins as well compared to the 3M and"/>
 <result pre="Fig 5 Antigen-specific CD4+ and CD8+ responses prior and after" exact="ZIKV" post="infection. The frequency of the specific response to DENV"/>
 <result pre="after ZIKV infection. The frequency of the specific response to" exact="DENV" post="and ZIKV antigens differs among cohorts. In all panels,"/>
 <result pre="infection. The frequency of the specific response to DENV and" exact="ZIKV" post="antigens differs among cohorts. In all panels, animals exposed"/>
 <result pre="antigens differs among cohorts. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="to different stimuli before (upper panel) and 30 days after" exact="ZIKV" post="infection (lower panel). (B) Analysis of CD8 T cell"/>
 <result pre="to different stimuli before (upper panel) and 30 days after" exact="ZIKV" post="infection (lower panel). Statistically significant differences among groups were"/>
 <result pre="colored lines represent the group that it is compared to." exact="DENV" post="12M animals had also a significantly higher frequency of"/>
 <result pre="also a significantly higher frequency of CD107a+ cells prior to" exact="ZIKV" post="infection (P&amp;lt;0.0001; mean diff.: -0.8775, CI95%: -1.25 to -0.503)"/>
 <result pre="mean diff.: -0.8775, CI95%: -1.25 to -0.503) against the whole" exact="DENV" post="antigen (Fig 5A, upper panel, right) while a significant"/>
 <result pre="increase in reactivity of CD107a+ CD4+ cells was observed against" exact="ZIKV" post="envelope and non-structural antigens on 30 days p.i. (P&amp;lt;0.05;"/>
 <result pre="contrast, data from CD8+ T cells denote similar responses between" exact="DENV" post="immune animals, with no significant variations compared to the"/>
 <result pre="to the naïve animals (Fig 5B). This suggests that previous" exact="DENV" post="immune status preferentially shapes the CD4+ T cells effector"/>
 <result pre="preferentially shapes the CD4+ T cells effector responses to a" exact="ZIKV" post="infection. Gating strategy is provided as S7 Fig. Pro-inflammatory"/>
 <result pre="as S7 Fig. Pro-inflammatory cytokines are not exacerbated by previous" exact="DENV" post="immunity Next, we determined how DENV immunity impacts the"/>
 <result pre="not exacerbated by previous DENV immunity Next, we determined how" exact="DENV" post="immunity impacts the cytokine secretion during a subsequent ZIKV"/>
 <result pre="how DENV immunity impacts the cytokine secretion during a subsequent" exact="ZIKV" post="infection (S8 Fig). Naïve macaques had significantly higher levels"/>
 <result pre="the collection period, but no other significant differences were detected." exact="DENV" post="12M animals had seemingly higher levels compared to their"/>
 <result pre="DENV 12M animals had seemingly higher levels compared to their" exact="DENV" post="3M counterparts, although no statistical significance was reached. From"/>
 <result pre="reached. From days 2 to 7 p.i., animals exposed to" exact="DENV" post="12 months before ZIKV infection had a consistently higher"/>
 <result pre="to 7 p.i., animals exposed to DENV 12 months before" exact="ZIKV" post="infection had a consistently higher expression of IFNγ compared"/>
 <result pre="animals (P&amp;lt;0.01; mean diff.: -1723, CI95%: -3060 to -385.1 versus" exact="DENV" post="12M; P&amp;lt;0.01; mean diff.: -1809, CI95%: -3305 to -313.18"/>
 <result pre="12M; P&amp;lt;0.01; mean diff.: -1809, CI95%: -3305 to -313.18 versus" exact="DENV" post="3M), but it decreased in the next 24 hours"/>
 <result pre="mean diff.: -533, CI95%: -22.69 to -1.98) (S8F Fig). Lastly," exact="DENV" post="12M animals showed higher levels of circulating perforin, reaching"/>
 <result pre="clearance. Other immune cell subsets frequency is shaped by previous" exact="DENV" post="exposure To establish how previous immunity to DENV shapes"/>
 <result pre="by previous DENV exposure To establish how previous immunity to" exact="DENV" post="shapes the cellular response against a subsequent ZIKV infection,"/>
 <result pre="immunity to DENV shapes the cellular response against a subsequent" exact="ZIKV" post="infection, an analysis of the involved cells was performed"/>
 <result pre="the involved cells was performed (S9 Fig). Animals exposed to" exact="DENV" post="3 months earlier had significantly higher frequency of B"/>
 <result pre="significantly higher frequency of B cells (CD20+) 24 hours before" exact="ZIKV" post="infection compared to the other groups (P&amp;lt;0.05; mean diff.:"/>
 <result pre="groups (P&amp;lt;0.05; mean diff.: -12.33, CI95%: -22.69 to -1.979 for" exact="DENV" post="3M versus DENV 12M, and P&amp;lt;0.01; mean diff.: 14.77,"/>
 <result pre="diff.: -12.33, CI95%: -22.69 to -1.979 for DENV 3M versus" exact="DENV" post="12M, and P&amp;lt;0.01; mean diff.: 14.77, CI95%: 4.41 to"/>
 <result pre="and P&amp;lt;0.01; mean diff.: 14.77, CI95%: 4.41 to 25.12 for" exact="DENV" post="3M versus naïve group). No other differences between groups"/>
 <result pre="increase in frequency at days 1 and 2 p.i. in" exact="DENV" post="12M animals in comparison with DENV 3M and naïve"/>
 <result pre="and 2 p.i. in DENV 12M animals in comparison with" exact="DENV" post="3M and naïve animals (P&amp;lt;0.01; mean diff.: 10.54, CI95%:"/>
 <result pre="animals (P&amp;lt;0.01; mean diff.: 10.54, CI95%: -2.65 to 18.43 for" exact="DENV" post="12M versus naïve animals on day 1 p.i.; for"/>
 <result pre="p.i., P&amp;lt;0.01; mean diff.: 13.68, CI95%: 4.87 to 22.50 for" exact="DENV" post="12M versus DENV 3M and, P&amp;lt;0.0001; mean diff.: 15.57,"/>
 <result pre="diff.: 13.68, CI95%: 4.87 to 22.50 for DENV 12M versus" exact="DENV" post="3M and, P&amp;lt;0.0001; mean diff.: 15.57, CI95%: 7.68 to"/>
 <result pre="and, P&amp;lt;0.0001; mean diff.: 15.57, CI95%: 7.68 to 23.45 for" exact="DENV" post="12M versus naïve animals) (Fig 6). Additionally, this group"/>
 <result pre="PBMCs. Naïve animals are depicted in black. Animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="depicted in black. Animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="their baseline. Discussion It is well established that exposure to" exact="DENV" post="prior to a ZIKV infection results in a qualitative"/>
 <result pre="is well established that exposure to DENV prior to a" exact="ZIKV" post="infection results in a qualitative modification of the humoral"/>
 <result pre="qualitative modification of the humoral and cellular immune response to" exact="ZIKV" post="in mice, macaques and humans [26, 34–37]. However, we"/>
 <result pre="macaques and humans [26, 34–37]. However, we know from sequential" exact="DENV" post="infections in humans that the timing between flavivirus exposure"/>
 <result pre="windows for vaccine candidates. Previously we have shown that a" exact="DENV" post="infection 2.8 years (late convalescence period) prior to ZIKV"/>
 <result pre="a DENV infection 2.8 years (late convalescence period) prior to" exact="ZIKV" post="exposure did not lead to an enhanced ZIKV infection."/>
 <result pre="prior to ZIKV exposure did not lead to an enhanced" exact="ZIKV" post="infection. Moreover, that period of convalescence results in an"/>
 <result pre="in an immune status that trends toward the control of" exact="ZIKV" post="viremia and the decrease of liver enzymes after infection."/>
 <result pre="this work, we aimed to establish the impact of different" exact="DENV" post="convalescent periods (3 months or early convalescent period, and"/>
 <result pre="months or middle convalescent period) on the immune response after" exact="ZIKV" post="infection. For the DENV 12M group, we identified a"/>
 <result pre="period) on the immune response after ZIKV infection. For the" exact="DENV" post="12M group, we identified a significant decline in the"/>
 <result pre="analysis for viremia, suggesting that the length of time after" exact="DENV" post="infection significantly impacts ZIKV replication and most likely its"/>
 <result pre="that the length of time after DENV infection significantly impacts" exact="ZIKV" post="replication and most likely its pathogenic effects. Two recent"/>
 <result pre="elapsed between two infections in the probability to have symptomatic" exact="ZIKV" post="infections. Results from a Nicaraguan pediatric cohort showed that"/>
 <result pre="cohort showed that when adjusted for age, sex, and recent" exact="DENV" post="infection (defined as 1–2 years before ZIKV infection, similar"/>
 <result pre="sex, and recent DENV infection (defined as 1–2 years before" exact="ZIKV" post="infection, similar to our DENV-middle convalescence immune group) was"/>
 <result pre="group) was significantly associated with a decreased risk of symptomatic" exact="ZIKV" post="infection. In addition, the same work showed that prior"/>
 <result pre="In addition, the same work showed that prior or recent" exact="DENV" post="infection did not affect the rate of total ZIKV"/>
 <result pre="recent DENV infection did not affect the rate of total" exact="ZIKV" post="infections [29]. Additionally, another work carried out at Pau"/>
 <result pre="of Salvador, Brazil, showed that the pre-outbreak IgG3 titers against" exact="DENV" post="NS1 were positively associated with risk of ZIKV infection"/>
 <result pre="titers against DENV NS1 were positively associated with risk of" exact="ZIKV" post="infection but at the same time the presence of"/>
 <result pre="antigen was associated to a decrease in the probability of" exact="ZIKV" post="infection [30]. This is highly relevant to our results"/>
 <result pre="our results because IgG3 subclass have been associated to recent" exact="DENV" post="infection and are detectable only up to 4 to"/>
 <result pre="months of our early-convalescent group showing a trend to control" exact="ZIKV" post="replication but not as effective as the DENV-middle convalescent"/>
 <result pre="no specific correlate of protection has been identified for these" exact="DENV" post="and ZIKV interactions in those human cohorts. Taking advantage"/>
 <result pre="correlate of protection has been identified for these DENV and" exact="ZIKV" post="interactions in those human cohorts. Taking advantage of our"/>
 <result pre="we completed a detailed analysis between the nAbs and the" exact="ZIKV" post="RNAemia within the first week of ZIKV infection that"/>
 <result pre="nAbs and the ZIKV RNAemia within the first week of" exact="ZIKV" post="infection that otherwise would be difficult to conduct in"/>
 <result pre="conduct in human cohorts. From days 5 to 7 after" exact="ZIKV" post="infection we identified a limited increase in the magnitude"/>
 <result pre="infection we identified a limited increase in the magnitude of" exact="ZIKV" post="neutralization activity in the DENV-middle convalescent group characterized by"/>
 <result pre="of low-to-intermediate levels of nAbs. This early expansion of the" exact="ZIKV" post="nAbs findings are in agreement with previous works with"/>
 <result pre="early expansion of the plasmablast response 6 days after secondary" exact="DENV" post="[44, 45] and primary ZIKV infections [46]. While no"/>
 <result pre="response 6 days after secondary DENV [44, 45] and primary" exact="ZIKV" post="infections [46]. While no correlation can be made with"/>
 <result pre="6 p.i., by day 7 a consistent increase in the" exact="ZIKV" post="nAbs correlating with the absence of RNAemia was observed"/>
 <result pre="absence of RNAemia was observed only in the animals of" exact="DENV" post="12M group. In order to determine if pre-existing DENV"/>
 <result pre="of DENV 12M group. In order to determine if pre-existing" exact="DENV" post="Abs mediate a correlate of protection by controlling early"/>
 <result pre="DENV Abs mediate a correlate of protection by controlling early" exact="ZIKV" post="replication, we performed depletion of DENV2 specific Abs from"/>
 <result pre="7 p.i. samples. Our results show that the neutralization against" exact="DENV" post="in both DENV-immune groups was abrogated while ZIKV neutralization"/>
 <result pre="neutralization against DENV in both DENV-immune groups was abrogated while" exact="ZIKV" post="neutralization remains unchanged. This result strongly suggests that pre-existing"/>
 <result pre="ZIKV neutralization remains unchanged. This result strongly suggests that pre-existing" exact="DENV" post="Abs play no role controlling ZIKV replication during the"/>
 <result pre="strongly suggests that pre-existing DENV Abs play no role controlling" exact="ZIKV" post="replication during the first week after infection and a"/>
 <result pre="the first week after infection and a contribution in limiting" exact="ZIKV" post="pathogenesis and clinical manifestations, as confirmed in NHPs and"/>
 <result pre="is unlikely. Interestingly, our results on the role of previous" exact="DENV" post="Abs on ZIKV replication contrast the findings from our"/>
 <result pre="our results on the role of previous DENV Abs on" exact="ZIKV" post="replication contrast the findings from our group in a"/>
 <result pre="infection scenario, suggesting that low-to-intermediary levels of cross-neutralizing Abs against" exact="DENV" post="induced by a previous ZIKV infection may play a"/>
 <result pre="levels of cross-neutralizing Abs against DENV induced by a previous" exact="ZIKV" post="infection may play a role in controlling early DENV"/>
 <result pre="previous ZIKV infection may play a role in controlling early" exact="DENV" post="RNAemia set point [47]. Additionally, we confirmed the pre-existence"/>
 <result pre="we confirmed the pre-existence of cross-reacting but non-neutralizing Abs to" exact="ZIKV" post="in the DENV-immune groups [32, 48]. However, those Abs"/>
 <result pre="the middle convalescent group. This confirms the high frequency of" exact="ZIKV" post="cross-reacting Abs during the early DENV convalescence that wane"/>
 <result pre="the high frequency of ZIKV cross-reacting Abs during the early" exact="DENV" post="convalescence that wane during the middle and late convalescent"/>
 <result pre="this current work, we can conclude that the neutralization against" exact="ZIKV" post="is very limited or absent in DENV-immune samples, regardless"/>
 <result pre="B cell response [46, 50]. Here we show that after" exact="ZIKV" post="infection, the levels of binding Abs to ZIKV NS1"/>
 <result pre="that after ZIKV infection, the levels of binding Abs to" exact="ZIKV" post="NS1 protein were significantly higher in the group with"/>
 <result pre="higher in the group with a middle convalescent period to" exact="DENV" post="compared to the other two groups which is in"/>
 <result pre="we found a significant early expansion in the magnitude of" exact="ZIKV" post="neutralization by days 6 and 7 after the infection."/>
 <result pre="studies carried out in human cohorts have suggested that prior" exact="DENV" post="exposure could modulate the humoral response to ZIKV [46,"/>
 <result pre="that prior DENV exposure could modulate the humoral response to" exact="ZIKV" post="[46, 51] while others have inferred that the effect"/>
 <result pre="maturation takes place in order to modify the response during" exact="ZIKV" post="infection. Lastly, earlier works suggested that the magnitude of"/>
 <result pre="DENV2 cross-reactive Abs in the pre-immune groups 30 days after" exact="ZIKV" post="infection with a rapid decline similar to baseline levels"/>
 <result pre="rapid decline similar to baseline levels by day 60 p.i." exact="DENV" post="cross-neutralizing Abs also show a slight but not significant"/>
 <result pre="p.i. compared to their baseline values. These results confirm that" exact="ZIKV" post="infection contributes to a transient expansion of DENV neutralization"/>
 <result pre="confirm that ZIKV infection contributes to a transient expansion of" exact="DENV" post="neutralization which may play a role modifying the course"/>
 <result pre="may play a role modifying the course of a subsequent" exact="DENV" post="infection in a DENV endemic region. Interestingly, the magnitude"/>
 <result pre="modifying the course of a subsequent DENV infection in a" exact="DENV" post="endemic region. Interestingly, the magnitude of the neutralization against"/>
 <result pre="Interestingly, the magnitude of the neutralization against the others 3" exact="DENV" post="serotypes was also boosted but without significant differences among"/>
 <result pre="in contrast with our previous work showing that time between" exact="ZIKV" post="and DENV infection significantly modify the magnitude of neutralization"/>
 <result pre="with our previous work showing that time between ZIKV and" exact="DENV" post="infection significantly modify the magnitude of neutralization to the"/>
 <result pre="infection significantly modify the magnitude of neutralization to the other" exact="DENV" post="serotypes suggesting that different immune mechanisms are triggered when"/>
 <result pre="during the convalescence period those Abs do not contribute to" exact="ZIKV" post="neutralization [31, 32]. Here we build on existing literature"/>
 <result pre="our results show that the expansion and durability of the" exact="DENV" post="nAbs induced by a secondary ZIKV infection is modest"/>
 <result pre="and durability of the DENV nAbs induced by a secondary" exact="ZIKV" post="infection is modest compared to the reported response induced"/>
 <result pre="compared to the reported response induced after a secondary heterologous" exact="DENV" post="infection [52, 53]. From our work, we can infer"/>
 <result pre="cellular immune response in facilitating the initial significant decrease of" exact="ZIKV" post="replication between days 4 to 7 p.i. is very"/>
 <result pre="profile of the CD4+ T cells present 12 months after" exact="DENV" post="infection and during heterologous ZIKV challenge correlates with better"/>
 <result pre="cells present 12 months after DENV infection and during heterologous" exact="ZIKV" post="challenge correlates with better performance relative to the early"/>
 <result pre="months) or late (2.8 years) [26] convalescence periods after primary" exact="DENV" post="infection. The role of CD4+T cells in flavivirus infection"/>
 <result pre="55]. Importantly, Weiskopf et al. and others have shown that" exact="DENV" post="CD4+ T cells are readily detectable early following DENV"/>
 <result pre="that DENV CD4+ T cells are readily detectable early following" exact="DENV" post="infection, and the frequency of DENV-specific CD107a+ CD4+ T"/>
 <result pre="of DENV-specific CD107a+ CD4+ T correlate with enhanced protection against" exact="DENV" post="disease [56, 57] and play a key role in"/>
 <result pre="[35]. Our work builds on these observations and demonstrates that" exact="DENV" post="specific CD4+ T cells isolated one year after DENV"/>
 <result pre="that DENV specific CD4+ T cells isolated one year after" exact="DENV" post="infection were highly responsive to the whole DENV virus"/>
 <result pre="year after DENV infection were highly responsive to the whole" exact="DENV" post="virus prior to ZIKV infection (characterized by a significantly"/>
 <result pre="were highly responsive to the whole DENV virus prior to" exact="ZIKV" post="infection (characterized by a significantly higher frequency of IFN-γ"/>
 <result pre="CD107a expressing CD4+ T cells in response to the whole" exact="ZIKV" post="and of IFN-γ CD4+ T cells after the other"/>
 <result pre="T cells after the other stimuli including the whole ZIKV," exact="ZIKV" post="and DENV envelope and ZIKV nonstructural proteins compared to"/>
 <result pre="after the other stimuli including the whole ZIKV, ZIKV and" exact="DENV" post="envelope and ZIKV nonstructural proteins compared to the other"/>
 <result pre="stimuli including the whole ZIKV, ZIKV and DENV envelope and" exact="ZIKV" post="nonstructural proteins compared to the other two groups. In"/>
 <result pre="of infection the focus of CD4+ T cells reactivity was" exact="ZIKV" post="envelope and non-structural antigens. That switch was a trend,"/>
 <result pre="significant in animals with an early period of convalescence to" exact="DENV" post="compared to the DENV-naïve group. Interestingly, it has been"/>
 <result pre="are associated with subclinical manifestations in children suffering from secondary" exact="DENV" post="infection [58]. Notably, the data for CD8+T cells did"/>
 <result pre="relatively similar responses between CD8+T cells isolated from the 12M" exact="DENV" post="immune animals compared to the 3M DENV immune animals."/>
 <result pre="from the 12M DENV immune animals compared to the 3M" exact="DENV" post="immune animals. Our finding on CD4+ T cells is"/>
 <result pre="disease outcome. The significant role of T cells in controlling" exact="ZIKV" post="replication in animals with a DENV-middle convalescence period before"/>
 <result pre="ZIKV replication in animals with a DENV-middle convalescence period before" exact="ZIKV" post="infection is reinforced by the significant increase of circulating"/>
 <result pre="a peak in perforin levels in serum 6 days after" exact="ZIKV" post="infection in animals with 2.8 years of previous immunity"/>
 <result pre="infection in animals with 2.8 years of previous immunity to" exact="DENV" post="[26]. Others have shown that Granzyme B levels in"/>
 <result pre="of the cellular immune response controlling the viral burden of" exact="ZIKV" post="in mice has been reported [62, 63]. More recently,"/>
 <result pre="[62, 63]. More recently, mouse models have shown that prior" exact="DENV" post="immunity can protect against ZIKV infection during pregnancy, and"/>
 <result pre="models have shown that prior DENV immunity can protect against" exact="ZIKV" post="infection during pregnancy, and CD8+ T cells are sufficient"/>
 <result pre="that on days 1 and 2 p.i. animals from the" exact="DENV" post="12M group had significant higher levels of pDC frequency"/>
 <result pre="higher levels of pDC frequency in comparison with animals from" exact="DENV" post="3M and naïve groups and with its own baseline"/>
 <result pre="levels. It has been shown that pDC levels correlate with" exact="DENV" post="severity, with various studies reporting a decrease in pDCs"/>
 <result pre="decrease in pDCs in patients with more serious forms of" exact="DENV" post="disease such as Dengue Hemorrhagic Fever (DHF) in comparison"/>
 <result pre="patients with more serious forms of DENV disease such as" exact="Dengue" post="Hemorrhagic Fever (DHF) in comparison with normal DENV or"/>
 <result pre="such as Dengue Hemorrhagic Fever (DHF) in comparison with normal" exact="DENV" post="or healthy patients [65, 66]. More importantly, De Carvalho"/>
 <result pre="colleagues reported that higher levels of pDCs correlate with lower" exact="DENV" post="viremia levels [67]. Other viral infections, like HIV-1 and"/>
 <result pre="the three cohorts in our work, the animals exposed to" exact="DENV" post="12 months before had the most efficient ZIKV viremia"/>
 <result pre="exposed to DENV 12 months before had the most efficient" exact="ZIKV" post="viremia clearance. pDC-mediated mechanisms have been described as key"/>
 <result pre="mechanisms have been described as key in antiviral responses against" exact="DENV" post="[69, 70]. It has been documented that mature pDCs"/>
 <result pre="IFN-γ production on CD4+ T cells in animals exposed to" exact="DENV" post="12 months before ZIKV infection. Altogether, our data reinforces"/>
 <result pre="T cells in animals exposed to DENV 12 months before" exact="ZIKV" post="infection. Altogether, our data reinforces that the activation of"/>
 <result pre="data reinforces that the activation of the adaptive response against" exact="DENV" post="and ZIKV infections involves signals and interactions from pDCs"/>
 <result pre="that the activation of the adaptive response against DENV and" exact="ZIKV" post="infections involves signals and interactions from pDCs and T"/>
 <result pre="pDCs correlating with the reported increase in the frequency of" exact="DENV" post="antigen specific T cells and a significant control of"/>
 <result pre="DENV antigen specific T cells and a significant control of" exact="ZIKV" post="replication observed only in the DENV 12M group denotes"/>
 <result pre="a significant control of ZIKV replication observed only in the" exact="DENV" post="12M group denotes that the complex interplay between the"/>
 <result pre="evidences supporting a limited role, if any, of the pre-existing" exact="DENV" post="humoral immune response controlling ZIKV replication. Furthermore, our work"/>
 <result pre="if any, of the pre-existing DENV humoral immune response controlling" exact="ZIKV" post="replication. Furthermore, our work indicates an early role of"/>
 <result pre="the precise role of the T cells immune response controlling" exact="ZIKV" post="viremia and pathogenesis, depletion of the specific T cells"/>
 <result pre="our results we cannot anticipate if the effect of previous" exact="DENV" post="immunity or the time between DENV and ZIKV infections"/>
 <result pre="the effect of previous DENV immunity or the time between" exact="DENV" post="and ZIKV infections may have any implications during pregnancy."/>
 <result pre="of previous DENV immunity or the time between DENV and" exact="ZIKV" post="infections may have any implications during pregnancy. However, studies"/>
 <result pre="any implications during pregnancy. However, studies addressing the role of" exact="DENV" post="Abs in pregnant women infected with ZIKV, one from"/>
 <result pre="from Italy and one from Brazil, concluded that pre-existence of" exact="DENV" post="Abs are not related to an increase of fetal"/>
 <result pre="damage [73, 74]. Moreover, the Brazilian study concluded that multitypic" exact="DENV" post="infections may protect, rather than enhance, from development of"/>
 <result pre="preprint, concluded that the time elapsed between the more recent" exact="DENV" post="epidemics in Brazil and the microcephaly epidemic observed after"/>
 <result pre="Brazil and the microcephaly epidemic observed after the introduction of" exact="ZIKV" post="was in fact relevant to either provide protection or"/>
 <result pre="impact for the epidemiological models anticipating the magnitude of new" exact="ZIKV" post="epidemics in DENV endemic areas and are essential for"/>
 <result pre="epidemiological models anticipating the magnitude of new ZIKV epidemics in" exact="DENV" post="endemic areas and are essential for the planning and"/>
 <result pre="areas and are essential for the planning and evaluation of" exact="ZIKV" post="and DENV vaccine schedules, design and monitoring. Methods Viral"/>
 <result pre="are essential for the planning and evaluation of ZIKV and" exact="DENV" post="vaccine schedules, design and monitoring. Methods Viral stock ZIKV"/>
 <result pre="and DENV vaccine schedules, design and monitoring. Methods Viral stock" exact="ZIKV" post="PRVABC59 strain was obtained from ATCC, BEI Resources (Manassas,"/>
 <result pre="order to compare results to our previously published data. This" exact="ZIKV" post="strain replicates well in rhesus macaques but has a"/>
 <result pre="in rhesus macaques but has a lower viremia peak than" exact="ZIKV" post="H/PF/2013 strain. We aimed to use a strain from"/>
 <result pre="Young adult rhesus macaques (4–7 years of age) seronegative for" exact="DENV" post="and ZIKV were housed in the CPRC facilities, University"/>
 <result pre="rhesus macaques (4–7 years of age) seronegative for DENV and" exact="ZIKV" post="were housed in the CPRC facilities, University of Puerto"/>
 <result pre="University of Puerto Rico, San Juan, Puerto Rico. For the" exact="ZIKV" post="challenge, macaques previously infected with DENV-2 in September 2016"/>
 <result pre="facilities in University of Puerto Rico, San Juan, Puerto Rico." exact="DENV" post="and ZIKV titration and neutralization assays For virus titration,"/>
 <result pre="University of Puerto Rico, San Juan, Puerto Rico. DENV and" exact="ZIKV" post="titration and neutralization assays For virus titration, Vero81 cells"/>
 <result pre="the FRNT or PRNT with 60% or greater reduction in" exact="DENV" post="or ZIKV foci or plaques (FRNT60 or PRNT60). A"/>
 <result pre="or PRNT with 60% or greater reduction in DENV or" exact="ZIKV" post="foci or plaques (FRNT60 or PRNT60). A positive neutralization"/>
 <result pre="manufacturer’s instructions. Real-time RT-PCR (TaqMan) assay-specific primers and probes for" exact="ZIKV" post="were designed by Sigma-Aldrich (St Louis, MO) following the"/>
 <result pre="and Research Laboratory Centers for Disease Control and Prevention (CDC)," exact="Dengue" post="Branch at San Juan, PR. RNA from other flaviviruses"/>
 <result pre="of RNA from a known amount of virus. ELISA for" exact="DENV" post="and ZIKV Prior to ZIKV challenge, DENV/ZIKV seronegative status"/>
 <result pre="from a known amount of virus. ELISA for DENV and" exact="ZIKV" post="Prior to ZIKV challenge, DENV/ZIKV seronegative status of cohort"/>
 <result pre="amount of virus. ELISA for DENV and ZIKV Prior to" exact="ZIKV" post="challenge, DENV/ZIKV seronegative status of cohort 3 animals was"/>
 <result pre="DENV/ZIKV seronegative status of cohort 3 animals was assessed using" exact="DENV" post="IgG/IgM and ZIKV NS1 IgG commercial kits (Focus Diagnostics,"/>
 <result pre="of cohort 3 animals was assessed using DENV IgG/IgM and" exact="ZIKV" post="NS1 IgG commercial kits (Focus Diagnostics, CA). After ZIKV"/>
 <result pre="and ZIKV NS1 IgG commercial kits (Focus Diagnostics, CA). After" exact="ZIKV" post="infection, seroreactivity to DENV was tested using commercial IgG"/>
 <result pre="commercial kits (Focus Diagnostics, CA). After ZIKV infection, seroreactivity to" exact="DENV" post="was tested using commercial IgG and IgM ELISA kits"/>
 <result pre="commercial IgG and IgM ELISA kits (Focus Diagnostics, Cypress, CA)." exact="ZIKV" post="IgG was assessed with available commercial kits (XpressBio, Frederick,"/>
 <result pre="of IgM levels against ZIKV, samples were tested using a" exact="ZIKV" post="IgM MAC-ELISA assay developed by Aravinda de Silva’s laboratory."/>
 <result pre="sample dilutions (1:40) were added. Positive and negative controls for" exact="ZIKV" post="and DENV were also prepared. Stock C6/36 ZIKV and"/>
 <result pre="(1:40) were added. Positive and negative controls for ZIKV and" exact="DENV" post="were also prepared. Stock C6/36 ZIKV and DENV antigens"/>
 <result pre="controls for ZIKV and DENV were also prepared. Stock C6/36" exact="ZIKV" post="and DENV antigens were diluted (1:2 and 1:3, respectively),"/>
 <result pre="ZIKV and DENV were also prepared. Stock C6/36 ZIKV and" exact="DENV" post="antigens were diluted (1:2 and 1:3, respectively), and added"/>
 <result pre="overnight with DENV-2 (NGC44) at a MOI of 0.1 or" exact="ZIKV" post="at a MOI of 0.5 in RPMI medium with"/>
 <result pre="Fig Vital signs and age of macaques before and after" exact="ZIKV" post="infection. Weight distribution per animal cohort. (A) Weight of"/>
 <result pre="(C) Rectal temperature (in Celsius) was measured. Animals exposed to" exact="DENV" post="12 months before ZIKV infection are depicted in blue,"/>
 <result pre="Celsius) was measured. Animals exposed to DENV 12 months before" exact="ZIKV" post="infection are depicted in blue, while animals exposed to"/>
 <result pre="ZIKV infection are depicted in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="and 30 days p.i. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="(TIF) LINK Click here for additional data file. S3 Fig" exact="Zika" post="RNA kinetics in urine. ZIKV RNA detection in urine"/>
 <result pre="additional data file. S3 Fig Zika RNA kinetics in urine." exact="ZIKV" post="RNA detection in urine though day 6 p.i. Animals"/>
 <result pre="detection in urine though day 6 p.i. Animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="day 6 p.i. Animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed 3 months"/>
 <result pre="profile of the three cohorts of macaques before and after" exact="ZIKV" post="infection. Humoral response was assessed using different commercial and"/>
 <result pre="data file. S5 Fig Geometric mean titers of dengue and" exact="ZIKV" post="neutralizing antibodies. Dilution titers against ZIKV during days 6"/>
 <result pre="titers of dengue and ZIKV neutralizing antibodies. Dilution titers against" exact="ZIKV" post="during days 6 and 7 post ZIKV infection. Animals"/>
 <result pre="Dilution titers against ZIKV during days 6 and 7 post" exact="ZIKV" post="infection. Animals from cohort 1 are shown in blue,"/>
 <result pre="for additional data file. S6 Fig Neutralizing response to heterologous" exact="DENV" post="serotypes and two different ZIKV strains. PRNT and FRNT"/>
 <result pre="Fig Neutralizing response to heterologous DENV serotypes and two different" exact="ZIKV" post="strains. PRNT and FRNT assays were performed to determine"/>
 <result pre="FRNT assays were performed to determine the effect of previous" exact="DENV" post="immunity in a subsequent ZIKV infection, and the neutralizing"/>
 <result pre="determine the effect of previous DENV immunity in a subsequent" exact="ZIKV" post="infection, and the neutralizing antibody response against different dengue"/>
 <result pre="serotypes and zika strains. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="Naïve animals are in black. (A) Neutralization against two different" exact="ZIKV" post="strains was performed. Dotted lines indicate the limit of"/>
 <result pre="of detection for the assay. (B) Neutralizing response against heterologous" exact="DENV" post="serotypes before and after ZIKV infection. (TIF) LINK Click"/>
 <result pre="(B) Neutralizing response against heterologous DENV serotypes before and after" exact="ZIKV" post="infection. (TIF) LINK Click here for additional data file."/>
 <result pre="cells expressing TNFa, IFNg and CD107a upon stimulation with various" exact="DENV" post="and ZIKV peptides is shown. (PDF) LINK Click here"/>
 <result pre="TNFa, IFNg and CD107a upon stimulation with various DENV and" exact="ZIKV" post="peptides is shown. (PDF) LINK Click here for additional"/>
 <result pre="here for additional data file. S8 Fig Previous exposure to" exact="DENV" post="modulates the cytokine and chemokine profiles after ZIKV infection."/>
 <result pre="exposure to DENV modulates the cytokine and chemokine profiles after" exact="ZIKV" post="infection. (A-G) Significant cytokine and chemokine profiles of are"/>
 <result pre="in pg per ml-1. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="data file. S9 Fig B cells profile before and after" exact="ZIKV" post="infection. Frequency of B cells was assessed. In all"/>
 <result pre="B cells was assessed. In all panels, animals exposed to" exact="DENV" post="12 months before ZIKV infection are in blue, while"/>
 <result pre="In all panels, animals exposed to DENV 12 months before" exact="ZIKV" post="infection are in blue, while animals exposed to DENV"/>
 <result pre="before ZIKV infection are in blue, while animals exposed to" exact="DENV" post="3 months before are in orange. Naïve animals are"/>
 <result pre="dendritic cells out of total gated PBMCs. Animals exposed to" exact="DENV" post="12 months before ZIKV infection are colored blue, while"/>
 <result pre="total gated PBMCs. Animals exposed to DENV 12 months before" exact="ZIKV" post="infection are colored blue, while animals exposed 3 months"/>
 <result pre="of the immunology data. References References 1CamposGC, SardiSI, SarnoM, BritesC." exact="Zika" post="virus infection, a new public health challenge. The Brazilian"/>
 <result pre="MonsS, LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control study. Lancet."/>
 <result pre="HerrmannC, PoullainP, TranTH, DeschampsN, MathonG, et al.Acute myelitis due to" exact="Zika" post="virus infection. Lancet. 2016;387(10026):148110.1016/S0140-6736(16)00644-9 .26946926 7FurtadoJM, EspositoDL, KleinTM, Teixeira-PintoT,"/>
 <result pre=".26946926 7FurtadoJM, EspositoDL, KleinTM, Teixeira-PintoT, da FonsecaBA. Uveitis Associated with" exact="Zika" post="Virus Infection. The New England journal of medicine. 2016;375(4):394–6."/>
 <result pre="de LamballerieX, HubertB, PiorkowskiG, et al.Evidence of Sexual Transmission of" exact="Zika" post="Virus. The New England journal of medicine. 2016;374(22):2195–8. Epub"/>
 <result pre="10MussoD, RocheC, RobinE, NhanT, TeissierA, Cao-LormeauVM. Potential sexual transmission of" exact="Zika" post="virus. Emerging infectious diseases. 2015;21(2):359–61. Epub 2015/01/28. 10.3201/eid2102.141363 .25625872"/>
 <result pre="HillsSL, OsterAM, PorseCC, DanylukG, ConeM, et al.Male-to-Female Sexual Transmission of" exact="Zika" post="Virus-United States, January-April 2016. Clinical infectious diseases: an official"/>
 <result pre="KhouriR, de Paula FreitasB, SiqueiraI, RibeiroGS, et al.Emergence of Congenital" exact="Zika" post="Syndrome: Viewpoint From the Front Lines. Annals of internal"/>
 <result pre="al.Hearing Loss in Infants with Microcephaly and Evidence of Congenital" exact="Zika" post="Virus Infection—Brazil, November 2015-May 2016. MMWR Morbidity and mortality"/>
 <result pre="14TeixeiraMG, Costa MdaC, de OliveiraWK, NunesML, RodriguesLC. The Epidemic of" exact="Zika" post="Virus-Related Microcephaly in Brazil: Detection, Control, Etiology, and Future"/>
 <result pre="disease caused by co-circulation and co-infection of dengue, chikungunya and" exact="Zika" post="in the Americas. Travel medicine and infectious disease. 2016;14(3):177–9."/>
 <result pre="KucirkaLM, BiQ, GrantzK, SaljeH, et al.Assessing the global threat from" exact="Zika" post="virus. Science (New York, NY). 2016;353(6300):aaf8160 Epub 2016/07/16. 10.1126/science.aaf8160"/>
 <result pre="DudleyDM, StewartLM, AliotaMT, KoenigMR, et al.Primary infection with dengue or" exact="Zika" post="virus does not affect the severity of heterologous secondary"/>
 <result pre="De La BarreraR, et al.Impact of prior flavivirus immunity on" exact="Zika" post="virus infection in rhesus macaques. PLoS pathogens. 2017;13(8):e100648710.1371/journal.ppat.1006487 .28771605"/>
 <result pre="NeryNJ, CastanhaPMS, SacramentoGA, et al.Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region. Science (New"/>
 <result pre="YoungE, LopezCA, BaricRS, et al.Lack of Durable Cross-Neutralizing Antibodies Against" exact="Zika" post="Virus from Dengue Virus Infection. Emerging infectious diseases. 2017;23(5):773–81."/>
 <result pre="et al.Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from" exact="Dengue" post="Virus Infection. Emerging infectious diseases. 2017;23(5):773–81. 10.3201/eid2305.161630 .28418292 33EstesJD,"/>
 <result pre="10.1038/s41577-018-0005-7 .29556017 34PriyamvadaL, SutharMS, AhmedR, WrammertJ. Humoral Immune Responses Against" exact="Zika" post="Virus Infection and the Importance of Preexisting Flavivirus Immunity."/>
 <result pre="10.1093/infdis/jix513 .29267924 35GrifoniA, PhamJ, SidneyJ, O’RourkePH, PaulS, PetersB, et al.Prior" exact="Dengue" post="virus exposure shapes T cell immunity to Zika virus"/>
 <result pre="et al.Prior Dengue virus exposure shapes T cell immunity to" exact="Zika" post="virus in humans. J Virol. 2017; Epub 2017/10/06. 10.1128/jvi.01469-17"/>
 <result pre="Epub 2017/10/06. 10.1128/jvi.01469-17 .28978707 36OsunaCE, WhitneyJB. Nonhuman Primate Models of" exact="Zika" post="Virus Infection, Immunity, and Therapeutic Development. The Journal of"/>
 <result pre="Epub 2017/12/22. 10.1093/infdis/jix540 .29267926 37WenJ, ShrestaS. T Cell Immunity to" exact="Zika" post="and Dengue Viral Infections. Journal of interferon &amp;amp; cytokine"/>
 <result pre="10.1093/infdis/jix540 .29267926 37WenJ, ShrestaS. T Cell Immunity to Zika and" exact="Dengue" post="Viral Infections. Journal of interferon &amp;amp; cytokine research: the"/>
 <result pre="al.Longitudinal Analysis of Memory B and T Cell Responses to" exact="Dengue" post="Virus in a 5-Year Prospective Cohort Study in Thailand."/>
 <result pre="et al.Viremia and Clinical Presentation in Nicaraguan Patients Infected With" exact="Zika" post="Virus, Chikungunya Virus, and Dengue Virus. Clinical infectious diseases:"/>
 <result pre="and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus," exact="Chikungunya" post="Virus, and Dengue Virus. Clinical infectious diseases: an official"/>
 <result pre="in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and" exact="Dengue" post="Virus. Clinical infectious diseases: an official publication of the"/>
 <result pre="DudleyDM, NewmanCM, MohrEL, GellerupDD, BreitbachME, et al.Heterologous Protection against Asian" exact="Zika" post="Virus Challenge in Rhesus Macaques. PLoS neglected tropical diseases."/>
 <result pre="et al.Does prior dengue virus exposure worsen clinical outcomes of" exact="Zika" post="virus infection? A systematic review, pooled analysis and lessons"/>
 <result pre="OnlamoonN, ZhengNY, HuangM, KovalenkovY, et al.B Cell Responses during Secondary" exact="Dengue" post="Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts."/>
 <result pre="47Pérez-GuzmánEX, PantojaP, Serrano-CollazoC, HassertMA, Ortiz-RosaA, RodríguezIV, et al.Time elapsed between" exact="Zika" post="and Dengue infections improves the immune response against Dengue"/>
 <result pre="Serrano-CollazoC, HassertMA, Ortiz-RosaA, RodríguezIV, et al.Time elapsed between Zika and" exact="Dengue" post="infections improves the immune response against Dengue without viremia"/>
 <result pre="between Zika and Dengue infections improves the immune response against" exact="Dengue" post="without viremia enhancement in rhesus macaques. bioRxiv. 2019:621094. 48LanciottiRS,"/>
 <result pre="LavenJJ, VelezJO, LambertAJ, JohnsonAJ, et al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007."/>
 <result pre="KatzelnickLC, Puerta-GuardoH, JadiR, et al.Longitudinal Analysis of Antibody Cross-neutralization Following" exact="Zika" post="Virus and Dengue Virus Infection in Asia and the"/>
 <result pre="et al.Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and" exact="Dengue" post="Virus Infection in Asia and the Americas. J Infect"/>
 <result pre="2018/04/05. 10.1093/infdis/jiy164 .29618091 50PriyamvadaL, HudsonW, AhmedR, WrammertJ. Humoral cross-reactivity between" exact="Zika" post="and dengue viruses: implications for protection and pathology. Emerging"/>
 <result pre="HartM, et al.Innate, T-, and B-Cell Responses in Acute Human" exact="Zika" post="Patients. Clinical infectious diseases: an official publication of the"/>
 <result pre="WeiskopfD. Cytotoxic CD4 T Cells: Differentiation, Function, and Application to" exact="Dengue" post="Virus Infection. Front Immunol. 2016;7:531 Epub 2016/12/23. 10.3389/fimmu.2016.00531 .28003809"/>
 <result pre="WolfKJ, SchwetyeKE, DiPaoloRJ, BrienJD, PintoAK. CD4+T cells mediate protection against" exact="Zika" post="associated severe disease in a mouse model of infection."/>
 <result pre="et al.Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent" exact="Zika" post="virus challenge. Nature communications. 2017;8(1):1459 Epub 2017/11/14. 10.1038/s41467-017-01669-z .29129917"/>
 <result pre=".29129917 63WenJ, TangWW, SheetsN, EllisonJ, SetteA, KimK, et al.Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
 <result pre=".28288094 64Regla-NavaJA, Elong NgonoA, ViramontesKM, HuynhAT, WangYT, NguyenAT, et al.Cross-reactive" exact="Dengue" post="virus-specific CD8(+) T cells protect against Zika virus during"/>
 <result pre="NguyenAT, et al.Cross-reactive Dengue virus-specific CD8(+) T cells protect against" exact="Zika" post="virus during pregnancy. Nature communications. 2018;9(1):3042 Epub 2018/08/04. 10.1038/s41467-018-05458-0"/>
 <result pre=".25566258 73PedrosoC, FischerC, FeldmannM, SarnoM, LuzE, Moreira-SotoA, et al.Cross-Protection of" exact="Dengue" post="Virus Infection against Congenital Zika Syndrome, Northeastern Brazil. Emerging"/>
 <result pre="LuzE, Moreira-SotoA, et al.Cross-Protection of Dengue Virus Infection against Congenital" exact="Zika" post="Syndrome, Northeastern Brazil. Emerging infectious diseases. 2019;25(8):1485–93. Epub 2019/05/11."/>
 <result pre="Association of past dengue fever epidemics with the risk of" exact="Zika" post="microcephaly at the population level in Brazil. Sci Rep."/>
 <result pre="Brazil. Sci Rep. 2020;10(1):1752 Epub 2020/02/06. 10.1038/s41598-020-58407-7 .32019953 76CostaF, KoAI." exact="Zika" post="virus and microcephaly: where do we go from here?The"/>
 <result pre=".29242092 77RobbianiDF, OlsenPC, CostaF, WangQ, OliveiraTY, NeryNJr., et al.Risk of" exact="Zika" post="microcephaly correlates with features of maternal antibodies. J Exp"/>
</results>
